Katya (Ethinylestradiol, Gestodene)

Ethinylestradiol, the estrogen component, binds to estrogen receptors and suppresses the hypothalamic‑pituitary‑ovarian axis, reducing the release of luteinizing hormone and follicle‑stimulating hormone. This inhibition prevents follicular development and ovulation, contributing to contraceptive efficacy.

The dosing regimen for Katya is determined by the prescribing healthcare professional. Typically, a combined oral contraceptive is taken once daily for a defined cycle, but the exact schedule and any placebo days are set by the prescriber based on clinical guidelines.

Katya must not be used during pregnancy; it is discontinued if pregnancy occurs. While limited data exist for breastfeeding, most guidelines advise caution and suggest alternative contraception, as estrogen may affect milk production and infant exposure.

To order Katya, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Katya contains gestodene, a third‑generation progestin, combined with ethynylestradiol. Compared with older formulations that use levonorgestrel, gestodene may offer a lower incidence of androgenic side effects such as acne, while maintaining similar contraceptive efficacy. Safety profiles are comparable, with individual tolerability varying.

Katya tablets should be stored at ambient temperature below 25 °C, in the original blister pack, protected from moisture and direct light. Do not store in bathrooms or near heat sources, and keep out of reach of children.

Katya is taken orally with a glass of water, preferably at the same time each day. The tablet is swallowed whole; it should not be chewed or broken. Consistent daily intake maximizes contraceptive reliability.

The most serious risks include venous thromboembolism, stroke, and rare hepatic adenomas. Women with a history of clotting disorders, uncontrolled hypertension, smoking over 15 cigarettes per day after age 35, or certain cardiovascular conditions should be closely monitored or avoid use.

Katya is contraindicated in women who are pregnant, have known or suspected estrogen‑dependent tumors, have a history of thromboembolic events, uncontrolled hypertension, severe liver disease, or who smoke heavily (more than 15 cigarettes per day) after age 35. It should also be avoided in individuals with known hypersensitivity to any component.